Healthcare professionals have chosen Lantus® for over 18 years1
A 52-week randomized study (N=570) designed to compare efficacy and safety of Lantus® plus OADs vs NPH plus OADs in patients with type 2 diabetes poorly controlled with OADs. Patients were randomized to either Lantus® (n=289) or NPH (n=281) at bedtime to reach a target FPG of <120 mg/dL. OADs were continued. Initial insulin dose and titration schedule were left to the discretion of the individual investigators. Primary endpoint was change in A1C.
In a pediatric clinical study, children and adolescents with T1DM had a higher incidence of severe symptomatic hypoglycemia in the 2 treatment groups (Lantus® or NPH) compared to adult trials with type 1 diabetes.
A 28-week, randomized, open-label, multicenter study of 349 patients with type 1 diabetes (aged 6-15) who received once-daily Lantus® (n=174) or once- or twice-daily NPH (n=175) in combination with regular human insulin as the mealtime insulin. The primary efficacy measure was mean change in A1C from baseline.
aSymptomatic hypoglycemia was defined as any event with clinical symptoms that could be confirmed by BG level <50 mg/dL.
bSevere hypoglycemia was defined as an event with symptoms consistent with hypoglycemia in which the subjects required the assistance of another person and which was associated with a BG level <50 mg/dL or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. This definition is consistent with that used in the Diabetes Control and Complications Trial.
This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. Important to note that if you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law.
Savings may vary depending on patients' out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.
Offer Terms for Lantus $0 Co-pay Savings Card
For the duration of the program, the Savings Card offers a $0 copay with a maximum savings up to $600 per box for prescriptions covered by private or commercial insurance. This offer is valid for up to 3 boxes per prescription.
Offer Terms for Insulins Valyou Savings Program ($99)
Sanofi insulins included in this program are: LANTUS® (insulin glargine injection) 100 Units/mL, TOUJEO® (insulin glargine injection) 300 Units/mL, ADMELOG® (insulin lispro injection) and APIDRA® (insulin glulisine injection) 100 Units/mL
This offer is not valid for prescriptions covered by commercial / private insurance. Only people without prescription medication insurance can apply for this offer. For the duration of the program, eligible patients will pay $99 for up to 10 vials or packs of pens per fill. Offer is valid for one fill per month. In order for you to pay $99 per month, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. This offer is not valid for the Max SoloStar pen. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.